Mesenchymal Stem Cells Hold Promise for Osteoarthritis and More Chronic Diseases

Video

Cynata Therapeutics' Ross Macdonald, PhD, discusses the company's pipeline and clinical-phase trials.

Stem cells have been a hot-button topic for some time now, the subject of quite a bit of hype and controversy, as well. As the dust continues to settle, it has become very clear that specifically mesenchymal stem cells represent a very promising therapeutic modality for diseases that are currently considered untreatable.

Cynata Therapeutics has developed a novel manufacturing platform, called Cymerus, that utilizes mesenchymoangioblasts derived from induced pluripotent stem cells to both economically and efficiently produce therapeutic mesenchymal stem cells that are of consistent quality.

The biotechnology company is pursuing the investigation of mesenchymal stem cell-based therapeutics in several indications, including osteoarthritis, critical limb ischemia, graft-versus-host disease, and acute respiratory distress syndrome, among others.

GeneTherapyLive sat down with Cynata's managing director and chief executive officer Ross Macdonald, PhD, to learn more about the company's clinical pipeline.

Recent Videos
David Barrett, JD, the chief executive officer of ASGCT
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
David Barrett, JD, the chief executive officer of ASGCT
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Related Content
© 2025 MJH Life Sciences

All rights reserved.